Tracers / [177Lu]Lu-DOTA-NI-FAPI-04
[177Lu]Lu-DOTA-NI-FAPI-04
Also written as [Lu-177]Lu-DOTA-NI-FAPI-04
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- Bivalent FAP-targeting agent containing a hypoxia-sensitive 2-nitroimidazole (NI) moiety conjugated to DOTA-FAPI-04
- Target / mechanism
- Fibroblast activation protein (FAP), with additional hypoxia-sensitive nitroimidazole moiety PMID 39710979
- Clinical application
- Solid tumors with hypoxic microenvironment; tumor theranostics PMID 39710979
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | DOTA-NI-FAPI-04 | 39710979 2025 J Med Chem |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-NI-FAPI-04, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.